VIDEO: Pros, cons of complement inhibitors debated at AAO meeting

ByCory Perla

Fact checked byChristine Klimanskis, ELS

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses controversies surrounding the use of complement inhibitors for the treatment of geographic atrophy.

“Complement inhibitors that were approved are still somewhat controversial, and it still generates a pretty lively discussion,” Miller said.

Miller touched on discussions that took place at the American Academy of Ophthalmology meeting about the quality of data supporting the approval of complement inhibitors, the side effects associated with their use, treatment burden and the lack of alternative treatment options.

“It’s not as bad as U.S. politics, but people are pretty passionate on both sides,” she said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Miller reports serving as a named inventor on patents and patent applications for ONL Therapeutics; serving as a consultant for ONL Therapeutics and Sumitomo Pharma Co.; serving in an advisory role for Drusolv Therapeutics; and receiving grant support from Lowy Medical Research Institute. Massachusetts Eye and Ear has a proprietary interest in photodynamic therapy and has received financial remuneration related to this technology. Miller reports receiving a share of the same in accordance with institutional guidelines.